Literature DB >> 19239361

Induction of HIV type 1 expression correlates with T cell responsiveness to mycobacteria in patients coinfected with HIV type 1 and Mycobacterium tuberculosis.

David H Canaday1, Mianda Wu, Shigou Lu, Htin Aung, Pierre Peters, Joy Baseke, Wilma Mackay, Harriet Mayanja-Kizza, Zahra Toossi.   

Abstract

An in vitro mononuclear cell system to model the microenvironment of coinfection with HIV-1 and Mycobacterium tuberculosis (MTB) was developed. This cellular system was used to assess the interaction of MTB-infected monocytes and T cells from dually infected HIV-1/TB patients with pulmonary tuberculosis (TB). Subjects with higher induction of HIV-1 gag/pol mRNA expression after MTB stimulation had increased MTB-specific T cell IFN-gamma and TNF-alpha production. Lack of HIV-1 mRNA induction did not correlate with increased induction of regulatory T cells (T-reg) as measured by MTB-induced Foxp3 mRNA. HIV-1 induction did not significantly correlate with clinical parameters including plasma HIV-1 viral load or CD4(+) T cell count. These data model MTB-induced HIV-1 replication at the microenvironment of MTB reactivation/infection. The data suggest that the magnitude of MTB-specific T cell responses drives local viral pathogenesis regardless of the stage of HIV-1 disease as reflected by plasma viral load or CD4(+) T cell count.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239361      PMCID: PMC2853903          DOI: 10.1089/aid.2008.0182

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  18 in total

1.  Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay.

Authors:  Michael Hoelscher; William E Dowling; Eric Sanders-Buell; Jean K Carr; Matthew E Harris; Angelika Thomschke; Merlin L Robb; Deborah L Birx; Francine E McCutchan
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

2.  Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation.

Authors:  Z Toossi; J L Johnson; R A Kanost; M Wu; H Luzze; P Peters; A Okwera; M Joloba; P Mugyenyi; R D Mugerwa; H Aung; J J Ellner; C S Hirsch
Journal:  J Acquir Immune Defic Syndr       Date:  2001-09-01       Impact factor: 3.731

3.  Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.

Authors:  C C Whalen; P Nsubuga; A Okwera; J L Johnson; D L Hom; N L Michael; R D Mugerwa; J J Ellner
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

4.  Transactivation of human immunodeficiency virus-1 in T-cells by Mycobacterium tuberculosis-infected mononuclear phagocytes.

Authors:  Zahra Toossi; Mianda Wu; Najmul Islam; Luciella Teixeira-Johnson; Rana Hejal; Htin Aung
Journal:  J Lab Clin Med       Date:  2004-08

Review 5.  Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease.

Authors:  Zahra Toossi
Journal:  J Infect Dis       Date:  2003-09-30       Impact factor: 5.226

6.  Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus.

Authors:  M M Lederman; D L Georges; D J Kusner; P Mudido; C Z Giam; Z Toossi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-07

Review 7.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Authors:  Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye
Journal:  Arch Intern Med       Date:  2003-05-12

8.  Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.

Authors:  Haruhiko Yagi; Takashi Nomura; Kyoko Nakamura; Sayuri Yamazaki; Toshio Kitawaki; Shohei Hori; Michiyuki Maeda; Masafumi Onodera; Takashi Uchiyama; Shingo Fujii; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2004-10-04       Impact factor: 4.823

Review 9.  Cytokines and HIV-1: interactions and clinical implications.

Authors:  K Kedzierska; S M Crowe
Journal:  Antivir Chem Chemother       Date:  2001-05

10.  Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.

Authors:  Noah Kiwanuka; Oliver Laeyendecker; Merlin Robb; Godfrey Kigozi; Miguel Arroyo; Francine McCutchan; Leigh Anne Eller; Michael Eller; Fred Makumbi; Deborah Birx; Fred Wabwire-Mangen; David Serwadda; Nelson K Sewankambo; Thomas C Quinn; Maria Wawer; Ronald Gray
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

View more
  6 in total

1.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

2.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

Review 3.  The aging immune system and its relationship to the development of chronic obstructive pulmonary disease.

Authors:  Gulshan Sharma; Nicola A Hanania; Y Michael Shim
Journal:  Proc Am Thorac Soc       Date:  2009-12-01

4.  Risk factors of tuberculosis infection among HIV/AIDS patients in Burkina Faso.

Authors:  Ziemlé Clément Méda; Issiaka Sombié; Olivier W C Sanon; Daouda Maré; Donald E Morisky; Yi-Ming Arthur Chen
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-09       Impact factor: 2.205

5.  Risk Factors of Active Tuberculosis in People Living with HIV/AIDS in Southwest Ethiopia: A Case Control Study.

Authors:  Mohammed Taha; Amare Deribew; Fasil Tessema; Sahilu Assegid; Luc Duchateau; Robert Colebunders
Journal:  Ethiop J Health Sci       Date:  2011-07

6.  Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria.

Authors:  Baba Maiyaki Musa; Babashani Musa; Hamza Muhammed; Nashabaru Ibrahim; Abubakar Garbati Musa
Journal:  Ann Thorac Med       Date:  2015 Jul-Sep       Impact factor: 2.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.